RU2706693C2 - Вирусная вакцина и способы ее производства - Google Patents
Вирусная вакцина и способы ее производства Download PDFInfo
- Publication number
- RU2706693C2 RU2706693C2 RU2016114285A RU2016114285A RU2706693C2 RU 2706693 C2 RU2706693 C2 RU 2706693C2 RU 2016114285 A RU2016114285 A RU 2016114285A RU 2016114285 A RU2016114285 A RU 2016114285A RU 2706693 C2 RU2706693 C2 RU 2706693C2
- Authority
- RU
- Russia
- Prior art keywords
- virus
- mass
- purified
- japanese encephalitis
- membrane
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 229960005486 vaccine Drugs 0.000 title claims abstract description 41
- 241000700605 Viruses Species 0.000 title claims description 133
- 238000004519 manufacturing process Methods 0.000 title claims description 28
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract description 114
- 210000003501 vero cell Anatomy 0.000 claims abstract description 48
- 238000000746 purification Methods 0.000 claims abstract description 36
- 230000002779 inactivation Effects 0.000 claims abstract description 29
- 208000015181 infectious disease Diseases 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000000427 antigen Substances 0.000 claims abstract description 13
- 102000036639 antigens Human genes 0.000 claims abstract description 13
- 108091007433 antigens Proteins 0.000 claims abstract description 13
- 230000012010 growth Effects 0.000 claims abstract description 9
- 229960004854 viral vaccine Drugs 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 104
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 71
- 230000003612 virological effect Effects 0.000 claims description 44
- 239000011159 matrix material Substances 0.000 claims description 39
- 239000012528 membrane Substances 0.000 claims description 36
- 239000003381 stabilizer Substances 0.000 claims description 35
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 34
- 239000000872 buffer Substances 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 17
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 17
- 239000004471 Glycine Substances 0.000 claims description 17
- 238000004113 cell culture Methods 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 16
- 239000000600 sorbitol Substances 0.000 claims description 16
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 15
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 15
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 15
- 229960000380 propiolactone Drugs 0.000 claims description 15
- 239000012465 retentate Substances 0.000 claims description 15
- 238000011026 diafiltration Methods 0.000 claims description 13
- 239000012535 impurity Substances 0.000 claims description 13
- 230000006641 stabilisation Effects 0.000 claims description 12
- 238000011105 stabilization Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229920000936 Agarose Polymers 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical group CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 claims description 5
- -1 sulfate ester Chemical class 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims 2
- 239000013065 commercial product Substances 0.000 claims 1
- 238000002270 exclusion chromatography Methods 0.000 claims 1
- 238000009776 industrial production Methods 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 27
- 239000002609 medium Substances 0.000 description 25
- 230000010261 cell growth Effects 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 238000000502 dialysis Methods 0.000 description 10
- 238000010899 nucleation Methods 0.000 description 10
- 229920006393 polyether sulfone Polymers 0.000 description 9
- 229960002920 sorbitol Drugs 0.000 description 9
- 230000006978 adaptation Effects 0.000 description 8
- 239000002033 PVDF binder Substances 0.000 description 7
- 230000000415 inactivating effect Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001471 micro-filtration Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 101710204837 Envelope small membrane protein Proteins 0.000 description 3
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 3
- 101710145006 Lysis protein Proteins 0.000 description 3
- 239000004695 Polyether sulfone Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000012365 batch cultivation Methods 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 229960003239 encephalitis vaccine Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4135/CHE/2013 | 2013-09-14 | ||
| IN4135CH2013 IN2013CH04135A (enrdf_load_html_response) | 2013-09-14 | 2014-09-08 | |
| PCT/IN2014/000585 WO2015059714A1 (en) | 2013-09-14 | 2014-09-08 | Emergency mode in a hybrid vehicle |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016114285A RU2016114285A (ru) | 2017-10-19 |
| RU2016114285A3 RU2016114285A3 (enrdf_load_html_response) | 2018-07-16 |
| RU2706693C2 true RU2706693C2 (ru) | 2019-11-20 |
Family
ID=52997726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016114285A RU2706693C2 (ru) | 2013-09-14 | 2014-09-08 | Вирусная вакцина и способы ее производства |
Country Status (6)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106232800B (zh) | 2014-03-25 | 2020-07-03 | 泰尔茂比司特公司 | 介质的被动替代 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| CA3209607A1 (en) * | 2015-07-16 | 2017-01-19 | Bharat Biotech International Limited | Vaccine compositions |
| WO2017083286A1 (en) | 2015-11-09 | 2017-05-18 | University Of Notre Dame | Particle size purification method and devices |
| JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| MY193736A (en) | 2017-11-03 | 2022-10-27 | Takeda Vaccines Inc | Method for inactivating zika virus and for determining the completeness of inactivation |
| AU2018375789B2 (en) | 2017-11-30 | 2021-11-11 | Takeda Vaccines, Inc. | Method for inactivating Zika virus and related methods |
| EP3581646A1 (en) * | 2018-06-15 | 2019-12-18 | Themis Bioscience GmbH | Integrated manufacturing and chromatographic system for virus production |
| KR102655828B1 (ko) | 2018-08-16 | 2024-04-08 | 이엠디 밀리포어 코포레이션 | 폐쇄된 바이오프로세싱 장치 |
| CN111394321A (zh) * | 2020-03-30 | 2020-07-10 | 无锡加莱克色谱科技有限公司 | 病毒颗粒纯化用超大孔径层析介质及其应用方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011762A1 (en) * | 1997-08-28 | 1999-03-11 | Cheil Jedang Corporation | An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine |
| WO2010137036A2 (en) * | 2009-05-25 | 2010-12-02 | Panacea Biotec Ltd | Novel japanese encephalitis vaccine and method of manufacturing the same |
| WO2012073257A2 (en) * | 2010-11-30 | 2012-06-07 | Bharat Biotech International Limited | Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals |
| WO2013130001A1 (en) * | 2012-02-29 | 2013-09-06 | Ge Healthcare Bio-Sciences Ab | Method for endotoxin removal |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100910B (zh) * | 2009-12-21 | 2013-01-23 | 北京清大天一科技有限公司 | 一种生产病毒疫苗的方法 |
-
2014
- 2014-09-08 IN IN4135CH2013 patent/IN2013CH04135A/en unknown
- 2014-09-08 RU RU2016114285A patent/RU2706693C2/ru active
- 2014-09-08 AU AU2014338520A patent/AU2014338520B2/en active Active
- 2014-09-08 CN CN201480050520.1A patent/CN105744952A/zh active Pending
- 2014-09-08 WO PCT/IN2014/000585 patent/WO2015059714A1/en active Application Filing
-
2016
- 2016-03-14 PH PH12016500500A patent/PH12016500500A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011762A1 (en) * | 1997-08-28 | 1999-03-11 | Cheil Jedang Corporation | An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine |
| WO2010137036A2 (en) * | 2009-05-25 | 2010-12-02 | Panacea Biotec Ltd | Novel japanese encephalitis vaccine and method of manufacturing the same |
| WO2012073257A2 (en) * | 2010-11-30 | 2012-06-07 | Bharat Biotech International Limited | Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals |
| WO2013130001A1 (en) * | 2012-02-29 | 2013-09-06 | Ge Healthcare Bio-Sciences Ab | Method for endotoxin removal |
Non-Patent Citations (4)
| Title |
|---|
| BADAM L., In vitro antiviral activity of indigenous glycyrrhizin, licorice and glycyrrhizic acid (Sigma) on Japanese encephalitis virus.J Commun Dis. 1997 Jun; 29(2):91-9. * |
| CHEN WR., et al., Genetic variation of Japanese encephalitis virus in nature.J Gen Virol. 1990 Dec;71 ( Pt 12):2915-22. * |
| SAKODA Y., et al., Purification of human and avian influenza viruses using cellulose sulfate ester (Cellufine Sulfate) * |
| SAKODA Y., et al., Purification of human and avian influenza viruses using cellulose sulfate ester (Cellufine Sulfate) in the process of vaccine production.Microbiol Immunol. 2012 Jul; 56(7):490-5. doi: 10.1111/j.1348-0421.2012.00468.x. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014338520A1 (en) | 2016-03-31 |
| AU2014338520B2 (en) | 2019-12-05 |
| CN105744952A (zh) | 2016-07-06 |
| IN2013CH04135A (enrdf_load_html_response) | 2015-08-14 |
| RU2016114285A3 (enrdf_load_html_response) | 2018-07-16 |
| RU2016114285A (ru) | 2017-10-19 |
| WO2015059714A8 (en) | 2015-06-18 |
| WO2015059714A1 (en) | 2015-04-30 |
| PH12016500500A1 (en) | 2016-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2706693C2 (ru) | Вирусная вакцина и способы ее производства | |
| EP1427817B1 (de) | Vermehrung von viren in zellkultur | |
| EP1427815B1 (de) | Verfahren zur grosstechnischen herstellung von impfstoffen | |
| US9957485B2 (en) | Systems and methods for virus propagation in cell cultures for vaccine manufacture | |
| ES2653197T3 (es) | Procedimiento para producir antígeno ortomixoviral y vacunas | |
| US6149917A (en) | Industrial production process for a vaccine against Japanese encephalitis virus and vaccine produced | |
| DE19612966A1 (de) | Tierische Zellen und Verfahren zur Vermehrung von Influenzaviren | |
| US20080193478A1 (en) | Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus | |
| US20210268405A1 (en) | Method for producing recombinant adenovirus | |
| CN101522209A (zh) | Ipv-dpt疫苗 | |
| CN101352569B (zh) | 二倍体细胞乙型脑炎疫苗及纯化乙型脑炎疫苗的制备方法 | |
| KR20120027381A (ko) | 일본뇌염 백신 및 그것의 제조 방법 | |
| US9932562B2 (en) | Drain down and re-feed of microcarrier bioreactor | |
| CN102614508B (zh) | 一种人用流感病毒裂解疫苗的病毒裂解灭活方法 | |
| CN116656628A (zh) | 一种痘病毒载体疫苗的制备方法 | |
| CN105296438A (zh) | 一种制备森林脑炎灭活疫苗的生产方法 | |
| KR101581228B1 (ko) | 바이러스의 증식을 위한 ２-단계 온도 프로파일 | |
| CN102343087A (zh) | 麻疹长-47株制备二倍体细胞减毒活疫苗及制备工艺 | |
| CN114272366B (zh) | 一种制备人用乙型脑炎灭活疫苗的方法及疫苗 | |
| CN1513553B (zh) | Vero细胞森林脑炎灭活疫苗 | |
| RU2683508C1 (ru) | Штамм вируса для изготовления вакцинных препаратов против геморрагической лихорадки с почечным синдромом (варианты) | |
| Yashaswini | Effect of ionic liquid buffered excipients on inactivation kinetics and storage stability of foot-and-mouth disease vaccine antigen | |
| HK1062029B (en) | Multiplication of viruses in a cell culture |